AIM ImmunoTech Secures European Patent for Ampligen Use
In an exciting development for AIM ImmunoTech Inc. (NYSE American: AIM), the Company announced the official granting of a European Patent No. 4,096,675. This patent, which is titled "Compositions for Treating LONG COVID," specifically covers innovative compositions that include AIM's proprietary double-stranded RNA (dsRNA) components, such as Ampligen (rintatolimod). This patent is a significant step forward in AIM’s strategy to explore potential therapies for Long COVID, a condition increasingly recognized for its debilitating fatigue.
CEO Comments on Patent Significance
AIM’s CEO, Thomas K. Equels, expressed optimism about this development. He noted that while the Company's primary focus remains on advancing its late-stage pancreatic cancer clinical program, securing this patent enhances their intellectual property portfolio. "This patent strengthens our belief in Ampligen's potential as a broad-spectrum immunotherapy," Equels stated. His remarks highlight the dual emphasis on addressing both cancer and Long COVID conditions, showcasing AIM's diverse therapeutic aspirations.
Scientific Rationale Behind Ampligen
Ampligen is designed to modulate the immune response. Scientific research, including in vitro and clinical studies, points to its early-onset antiviral effects, stimulating a robust innate immune response. Historical experiments conducted by the Company on SARS-CoV-1 revealed a marked decrease in viral replication, indicating similar potential for SARS-CoV-2, specifically in patients suffering from Long COVID. Such findings are pivotal in understanding how Ampligen could serve as a powerful therapeutic option in the face of ongoing post-COVID complications.
Clinical Studies and Results
AIM ImmunoTech conducted a Phase 2 study, referred to as AMP-518, to evaluate Ampligen's efficacy and safety for treating those experiencing Long COVID symptoms, particularly fatigue. Positive topline results from this trial demonstrated that participants tolerated Ampligen well, and showed promising evidence that it may alleviate fatigue among post-COVID patients. Following further analysis, the Company is encouraged that Ampligen could provide necessary therapeutic relief for individuals grappling with moderate-to-severe Long COVID.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an innovative immuno-pharmaceutical company dedicated to developing therapies that target numerous types of cancers, immune disorders, and viral diseases, inclusive of COVID-19. The flagship product, Ampligen (rintatolimod), is classified as a first-in-class investigational drug designed to act as a TLR3 agonist, possessing specific immuno-modulatory properties. The potential applications of Ampligen extend to various significant cancers and viral disease contexts, enhancing AIM's mission to address critical health challenges.
Stay Connected for Updates
To keep abreast of AIM ImmunoTech's advancements, interested parties can find more information on the official website. The Company is also active on social platforms such as X, LinkedIn, and Facebook, where updates on clinical trials, patent achievements, and new therapeutic developments are regularly shared.
Frequently Asked Questions
What is the significance of the European Patent granted to AIM?
The patent grants AIM ImmunoTech intellectual property protection for Ampligen's use in treating Long COVID, reinforcing its market position.
What role does Ampligen play in treating Long COVID?
Ampligen is proposed to potentially reduce fatigue in Long COVID patients by modulating the immune response.
What are the results of the AMP-518 clinical trial?
The AMP-518 trial showed that Ampligen was generally well tolerated and may help alleviate fatigue in patients with Long COVID.
How does Ampligen function in the immune system?
Ampligen acts as a dsRNA and TLR3 agonist, promoting a strong immune response against viral infections.
Where can I find more information about AIM ImmunoTech?
Further details can be accessed on AIM's official website and its social media channels on X, LinkedIn, and Facebook.
